Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Acute NMOSD Attack
NCT06673394Phase 2Withdrawn
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of eculizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Optic-Spinal Impairment Scale at 28 days. Planned start Sep 2025; status: withdrawn.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06673394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673394.